PReS-FINAL-2333: Long term efficacy of interleukin-1 receptor antagonist (anakinra) in a multicentric cohort of patients affected by idiopathic recurrent pericarditis by M Finetti et al.
POSTER PRESENTATION Open Access
PReS-FINAL-2333: Long term efficacy of
interleukin-1 receptor antagonist (anakinra) in a
multicentric cohort of patients affected by
idiopathic recurrent pericarditis
M Finetti1*, A Insalaco2, L Cantarini3, M D’Alessandro1, A Meini4, L Breda5, M Alessio6, P Picco1, A Martini1,
M Gattorno1
From 20th Pediatric Rheumatology European Society (PReS) Congress
Ljubljana, Slovenia. 25-29 September 2013
Introduction
Recurrent pericarditis represents an important complica-
tion of acute pericarditis. Therapeutic approach during
recurrences consists of NSAID (non-steroidal anti-inflam-
matory drugs) administration. However steroid is often
necessary to control disease flares. IL-1 inhibitors efficacy
has been anecdotally described as effective in the control
of the disease in steroid-dependent and colchicine-
resistant patients.
Objectives
To evaluate the long term response to treatment with
anakinra (IL-1 receptor antagonist) in a multicenter
cohort of patients (pts) affected by idiopathic recurrent
pericarditis.
Methods
Fifteen pts (12 pediatrics, 3 adults; M:F = 11:4) followed
by 6 national referral centers were enrolled in the study.
The mean age was 22 years (range 8-60 yrs); mean age
at onset 16 years (5-49 yrs), mean age at the beginning
of treatment 19 years (6-56 yrs). All pts received an
initial dosage of 1-2 mg/Kg/die. All pts were steroid-
dependent and 14 of them had received colchicine.
Recurrence was documented in patients who presented
typical chest pain and 1 or more of the following signs:
fever, rubs, electrocardiographic changes, pericardial
effusion, increase of acute phase reactants. Outcomes
evaluated in our study were i)response to anakinra,
defined as resolution of pericardial symptoms associated
to normalization of laboratory-instrumental findings after
first administration of the drug; ii)long term remission
during IL-1 receptor antagonist regimen defined as
absence of relapses during monotherapy; iii)resolution
after anakinra discontinuation.
Results
All pts that received anakinra during active disease (13
pts) presented a dramatic response with a very rapid
disappearance of precordial pain, fever, rubs and
normalization of acute phase reactants within a few
hours from drug administration. Continuous therapy
allowed rapid tapering and then discontinuation of
steroid, colchicine and NSAID. During continuous daily
treatment (mean FU = 12 months, range 5-17 months),
no pt presented a relapse of the disease; 14 pts started
tapering and 8 of them experienced a relapse (mean
time since tapering start to relapse = 9 months, range
2-17 months). In all pts disease flare was successfully
and quickly controlled by daily full-dose administration
of anakinra, without the requirement of any steroid
treatment. A total of 10 flares has been observed in
these 8 pts. In 5 pts Anakinra was successfully discon-
tinued after 24 months of treatment (range 17-32
months). The mean time of remission since the with-
drawn of the drug is now 12 months (range 2-24
months). At the last follow-up all pts were in remission.
Three pts are still receiving daily administration of ana-
kinra as monotherapy. In 7 patients anakinra tapering is
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Conclusion
The long term use of anakinra in monotherapy is asso-
ciated to a persistent control of clinical-laboratoristic-
instrumental features of idiopathic recurrent pericarditis.
In almost 50% of the patients reactivation of clinical
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